tiprankstipranks
Trending News
More News >

Maze Therapeutics initiated with an Outperform at Wedbush

Wedbush initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and $17 price target

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1